Mercado cerrado
Athira Pharma/ATHA
13:30
15:10
16:45
18:25
20:00
1D1S1MAHF1A5Y
Acerca de Athira Pharma
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
Símbolo
ATHA
Sector
Cotiza en
Industria
Productos farmacéuticos
Sede central
Empleados
66
Página web
Métricas de Athira Pharma
BásicoAvanzado
119 M$
Capitalización
-
PER
-2,97 $
BPA
2.91
Beta
-
Dividendos
Precio y volumen
Capitalización
119 M$
Beta
2.91
Solvencia financiera
Ratio de solvencia
3,966
Test ácido
3,472
Ratio de endeudamiento a largo plazo
1,219
Ratio de endeudamiento total
1,688
Eficacia de la gestión
Rendimiento de los activos (TTM)
-47,53 %
Rentabilidad de los fondos propios (TTM)
-84,57 %
Valoración
Ratio precio-valor contable
1,44
Ratio precio-valor contable neto (TTM)
1,44
Ratio precio-flujo de caja libre (TTM)
-1,199
Crecimiento
Variación del beneficio por acción (TTM)
4,43 %
Crecimiento de los beneficios por acción en 3 años (CAGR)
29,07 %
Qué piensan los analistas de Athira Pharma
Valoración de los Analistas
Calificaciones de analistas (comprar, conservar, vender) para la acción Athira Pharma.
Rendimiento financiero de Athira Pharma
Cuenta de resultados
Ingresos y gastos
TrimestralAnual
Q3 24
Crecimiento intertrimestral
Ingresos
37 mil M$
-39,75 %
Beneficios
45 mil M$
107,52 %
Margen de beneficio
37,65 %
6,78 %
Rentabilidad de Athira Pharma
Beneficios por acción (BPA)
Rentabilidad de la empresa
TrimestralAnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Real
3,69 $
2,85 $
2,45 $
2,42 $
-
Previsto
3,55 $
2,61 $
2,05 $
2,31 $
3,94 $
Sorpresa
3,94 %
9,20 %
19,51 %
4,63 %
-
Noticias de Athira Pharma
TodosArtículosVídeos
![Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates](/_next/image?url=https%3A%2F%2Fcdn.snapi.dev%2Fimages%2Fv1%2Fq%2Fq%2Fpress16-2562311.jpg&w=3840&q=75)
Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates
GlobeNewsWire·hace 4 semanas
![Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer's Disease-Related Pathology at the Alzheimer's Association International Conference (AAIC) 2024](/_next/image?url=https%3A%2F%2Fcdn.snapi.dev%2Fimages%2Fv1%2F9%2Fx%2Fpress1-2556894.jpg&w=3840&q=75)
Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer's Disease-Related Pathology at the Alzheimer's Association International Conference (AAIC) 2024
GlobeNewsWire·hace 1 mes
![Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients](/_next/image?url=https%3A%2F%2Fcdn.snapi.dev%2Fimages%2Fv1%2F2%2Fr%2Fpress20-2475139.jpg&w=3840&q=75)
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients
GlobeNewsWire·hace 3 meses
Los datos expuestos son meramente indicativos y no se garantiza que sean exactos o completos. El precio de ejecución real puede variar. Rentabilidades pasadas no son indicativas de resultados futuros. Tu rentabilidad puede verse afectada por las fluctuaciones monetarias y las comisiones y gastos aplicables. Capital en riesgo.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.